U.S. markets close in 2 hours 44 minutes

Novacyt S.A. (ALNOV.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
4.9650+0.2780 (+5.93%)
At close: 5:37PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.6870
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.8780 - 5.3500
52 Week Range2.3100 - 13.9600
Avg. Volume1,594,370
Market Cap350.659M
Beta (5Y Monthly)-3.48
PE Ratio (TTM)8.33
EPS (TTM)0.5960
Earnings DateApr 15, 2021 - Apr 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Novacyt launches test to differentiate COVID-19 and flu

      Novacyt launches test to differentiate COVID-19 and flu

      Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test on Thursday to differentiate between COVID-19 and common winter diseases. Novacyt said its "Winterplex" test panel included two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV). "We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases," Novacyt CEO Graham Mullis said.

    • Reuters

      Diagnostics group Novacyt to launch more COVID-19 testing products

      Clinical diagnostics company Novacyt - one of many healthcare companies whose shares have surged during the pandemic - announced on Monday more new products to test for the presence of the coronavirus. Novacyt said it was developing a respiratory testing panel to diagnose and distinguish between the 'A' and 'B' types of influenza, the respiratory syncytial virus (RSV) and COVID-19, with the launch of this product expected in September in time for the 2020/21 flu season in the northern hemisphere. "The immediate pipeline of new products is expected to drive incremental revenue for the company in the near-term, but Novacyt's strengthened financial position also means we are able to redefine our R&D pipeline for the next three years, which we expect to drive significant and continued growth opportunities in the longer-term," said Novacyt CEO Graham Mullis.

    • Investing.com

      StockBeat: Novacyt Starts to Deliver

      By Geoffrey Smith